|Comparison of the AdvanSure Human Papillomavirus Screening Real-Time PCR, the Abbott RealTime High Risk Human Papillomavirus Test, and the Hybrid Capture Human Papillomavirus DNA Test for the Detection of Human Papillomavirus
|Yusun Hwang, M.D. and Miae Lee, M.D.|
|Department of Laboratory Medicine, Ewha Womans University School of Medicine, Seoul, Korea|
|Background: We evaluated the performance of various commercial assays for the molecular
detection of human papillomavirus (HPV); the recently developed AdvanSure HPV
Screening real-time PCR assay (AdvanSure PCR) and the Abbott RealTime High Risk HPV
PCR assay (Abbott PCR) were compared with the Hybrid Capture 2 HPV DNA Test (HC2).
Methods: All 3 tests were performed on 177 samples, and any sample that showed a discrepancy
in any of the 3 tests was genotyped using INNO-LiPA HPV genotyping and/or
sequencing. On the basis of these results, we obtained a consensus HPV result, and the
performance of each test was evaluated. We also evaluated high-risk HPV 16/18 detection
by using the 2 real-time PCR assays.
Results: Among the 177 samples, 65 were negative and 75 were positive in all 3 assays;
however, the results of the 3 assays with 37 samples were discrepant. Compared with the
consensus HPV result, the sensitivities and specificities of HC2, AdvanSure PCR, and Abbott
PCR were 97.6%, 91.7%, and 86.9% and 83.9%, 98.8%, and 100.0%, respectively.
For HPV type 16/18 detection, the concordance rate between the AdvanSure PCR and
Abbott PCR assays was 98.3%; however, 3 samples were discrepant (positive in AdvanSure
PCR and negative in Abbott PCR) and were confirmed as HPV type 16 by INNO-LiPA
genotyping and/or sequencing.
Conclusions: For HPV detection, the AdvanSure HPV Screening real-time PCR assay and
the Abbott PCR assay are less sensitive but more specific than the HC2 assay, but can simultaneously
differentiate type 16/18 HPV from other types.|
2012 May; 32(03) 201-205
|DOI : http://dx.doi.org/10.3343/alm.2012.32.3.201